Iovance Biotherapeutics, Inc.
IOVANASDAQHealthcare● Active
$4.12
$-0.11(-2.54%)
Market Cap$1.5B
P/E Ratio—
52W High$5.63
52W Low$1.66
Iovance Biotherapeutics, Inc. (IOVA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IOVA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.26B | $0.16B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.01B | $0.12B | $0.01B | $0.00B | $0.00B |
| Gross Profit | $0.26B | $0.04B | ($0.01B) | $0.00B | $0.00B |
| Gross Margin %(computed) | 97.23% | 24.43% | -804.54% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.30B | $0.28B | $0.34B | $0.29B | $0.26B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.10B | $0.08B |
| Total Operating Expenses | $0.66B | $0.44B | $0.45B | $0.40B | $0.34B |
| Operating Income | ($0.40B) | ($0.40B) | ($0.46B) | ($0.40B) | ($0.34B) |
| Operating Margin %(computed) | -153.08% | -240.92% | — | — | — |
| Interest Income | $0.00B | $0.02B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.39B) | ($0.38B) | ($0.45B) | ($0.40B) | ($0.34B) |
| Income Tax Expense | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B | $0.00B |
| Net Income | ($0.39B) | ($0.37B) | ($0.44B) | ($0.40B) | ($0.34B) |
| Net Margin %(computed) | -148.38% | -226.84% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
| Wtd Avg Shares | 0.36B | 0.29B | 0.24B | 0.16B | 0.15B |
| EBITDA | ($0.36B) | ($0.35B) | ($0.43B) | ($0.38B) | ($0.33B) |
| EBITDA Margin %(computed) | -135.52% | -214.34% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Iovance Biotherapeutics, Inc. data
About Iovance Biotherapeutics, Inc. (IOVA) Income Statement
Iovance Biotherapeutics, Inc. (IOVA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IOVA reported revenue of $0.26B, gross profit of $0.26B (gross margin 97.23%), and net income of ($0.39B) — a net profit margin of -148.38%.
Frequently asked questions
IOVA · 4 questionsIovance Biotherapeutics, Inc. (IOVA) reported revenue of $0.26B for 2025, up 60.6% year-over-year.
IOVA revenueIOVA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08